ReviewCurrent diabetes reviews2011
The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy.
Review in Current diabetes reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 47 citations in OpenAlex.
- Longitudinal metabolite and protein trajectories prior to diabetes mellitus diagnosis in Danish blood donors: a nested case-control study.Diabetologia · 2024Article
- Targeting Macrophages: Therapeutic Approaches in Diabetic Kidney Disease.International journal of molecular sciences · 2024Review
- The Role of the Endocrine System in the Regulation of Acid-Base Balance by the Kidney and the Progression of Chronic Kidney Disease.International journal of molecular sciences · 2024Review
- Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders.Neurotoxicity research · 2022Review
- Renal effects of growth hormone in health and in kidney disease.Pediatric nephrology (Berlin, Germany) · 2021Article
- Growth hormone induces mitotic catastrophe of glomerular podocytes and contributes to proteinuria.Cell death & disease · 2021Article
- Growth hormone induces Notch1 signaling in podocytes and contributes to proteinuria in diabetic nephropathy.The Journal of biological chemistry · 2019Article
- The effects of growth hormone on therapy resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- Elevated expression levels of serum insulin-like growth factor-1, tumor necrosis factor-α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy.Journal of diabetes investigation · 2017Article
- Novel Actions of Growth Hormone in Podocytes: Implications for Diabetic Nephropathy.Frontiers in medicine · 2017Review
- Notoginsenoside R1 ameliorates podocyte injury in rats with diabetic nephropathy by activating the PI3K/Akt signaling pathway.International journal of molecular medicine · 2016Article
- Growth hormone (GH)-transgenic insulin-like growth factor 1 (IGF1)-deficient mice allow dissociation of excess GH and IGF1 effects on glomerular and tubular growth.Physiological reports · 2016Article
- Glucose Homeostasis and Cardiovascular Alterations in Diabetes.Comprehensive Physiology · 2015Review
- Male bovine GH transgenic mice have decreased adiposity with an adipose depot-specific increase in immune cell populations.Endocrinology · 2015Article
- Glomerular endothelial cell injury and cross talk in diabetic kidney disease.American journal of physiology. Renal physiology · 2015Review
- The novel role of TRPC6 in vitamin D ameliorating podocyte injury in STZ-induced diabetic rats.Molecular and cellular biochemistry · 2015Article
- Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications.Molecular and cellular endocrinology · 2014Review
- Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus.Frontiers in endocrinology · 2014Review
- Metabolic syndrome and associated chronic kidney diseases: nutritional interventions.Reviews in endocrine & metabolic disorders · 2013Review
- Human conditions of insulin-like growth factor-I (IGF-I) deficiency.Journal of translational medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Involvement of the growth hormone (GH) / insulin-like growth factor 1 (IGF-I) axis in the pathogenesis of diabetic nephropathy (DN) is strongly suggested by studies investigating the impact of GH excess and deficiency on renal structure and function. GH excess in both the human (acromegaly) and in transgenic animal models is characterized by significant structural and functional changes in the kidney. In the human a direct relationship has been noted between the activity of the GH/IGF-1 axis and renal hypertrophy, microalbuminuria, and glomerulosclerosis. Conversely, states of GH deficiency or deficiency or inhibition of GH receptor (GHR) activity confer a protective effect against DN. The glomerular podocyte plays a central and critical role in the structural and functional integrity of the glomerular filtration barrier and maintenance of normal renal function. Recent studies have revealed that the glomerular podocyte is a target of GH action and that GH's actions on the podocyte could be detrimental to the structure and function of the podocyte. These results provide a novel mechanism for GH's role in the pathogenesis of DN and offer the possibility of targeting the GH/IGF-1 axis for the prevention and treatment of DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.